$81M Acquisition Signals Push Toward Scalable Oncology AI
Tempus AI has acquired Paige, a digital pathology company spun out of Memorial Sloan Kettering, for $81.25 million, giving Tempus access to a vast archive of nearly 7 million digitized pathology slides and corresponding clinical and molecular data. The deal primarily involves stock and includes Paige’s commitments under a Microsoft Azure cloud services agreement.
The acquisition aligns with Tempus’ strategic goal to build the largest foundation model in oncology. Paige previously developed a foundation model using 1 million digitized slides and received multiple regulatory clearances in the US and Europe for artificial intelligence (AI) tools, including those aiding in prostate cancer diagnosis. Tempus plans to use Paige’s broader dataset—collected from 45 countries across diverse populations—to further its ambitions in clinical AI development.
Lefkofsky emphasized that the deal complements Tempus’ existing strategy and will not change its financial trajectory. “You should expect us to be disciplined in terms of what we acquire,” he said. “You should expect it to be synergistic, plug some kind of hole within the company that we believe is strategic and important and not be some kind of crazy left turn.”
Paige had previously raised over $220 million and partnered with companies such as Philips, Quest Diagnostics, and Microsoft. However, the acquisition price reflects less than 40% of its disclosed funding.
The acquisition follows a series of targeted moves by Tempus, including its recent $17.4 million acquisition of Deep 6 AI and a $600 million deal for Ambry Genetics. The Paige deal reinforces Tempus’ commitment to expanding its data and AI application footprint in oncology while maintaining a clear path toward profitability.
Reference
Taylor N P. Tempus inks $81M Paige buyout to support AI model development. MedTechDive. Published August 26, 2025. Accessed September 9, 2025. https://www.medtechdive.com/news/tempus-paige-buyout-acquisition-ai/758589/
